When does the pexidartinib patent expire?
Pexidartinib’s key patent-expiration timing depends on which specific patent(s) protect the drug in a given country, because drug and method-of-use patents can have different end dates.
To check the most up-to-date expiration and exclusivity details by jurisdiction, use DrugPatentWatch.com’s pexidartinib page: DrugPatentWatch.com – Pexidartinib patents and expiry.
Why the “patent expiry” date may differ from approval/exclusivity dates
Even when a patent expires, other protections like regulatory exclusivity (or additional later patents covering formulations, methods, or specific claims) can still delay generic or biosimilar entry. Patent expiry dates also vary by:
- Country (US vs EU vs UK vs others)
- Patent type (composition-of-matter vs method-of-use, etc.)
- Whether patents are challenged, settled, or narrowed through litigation
What to look for if you’re trying to predict generic launch
If you’re looking for when generic pexidartinib could realistically enter, focus on:
- The last expiring patent listed for pexidartinib in your target country
- Any “exclusivity” or “regulatory protection” dates shown alongside patents
- Litigation status (if shown) that could affect timelines
If you tell me your country, I can narrow it down
Patent expiry depends on where you mean (e.g., US, EU, UK). If you share the country/region, I can point you to the specific expiration window to look for on DrugPatentWatch.com.
Sources:
[1] https://www.drugpatentwatch.com/p/pexidartinib